AGRX - AGILE THERAPEUTICS INC
Previous close
1.51
0 0%
Share volume: 56,184
Last Updated: Mon 26 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$1.51
0.00
0.00%
Fundamental analysis
5%
Profitability
0%
Dept financing
5%
Liquidity
50%
Performance
0%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
0 0%
2 Year
0 0%
Key data
Stock price
$1.51
DAY RANGE
$1.51 - $1.52
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Alfred F. Altomari
Region: US
Website: agiletherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: agiletherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Agile Therapeutics, Inc. researches, develops, and commercializes prescription contraceptive products. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of line extensions and other products.
Recent news